1-2 of 2
Wieslaw Jedrzejczak, MD
Close
Sort by
Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Gail J. Roboz, MD, Hartmut Döhner, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw Jedrzejczak, MD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Jean-Pierre Issa, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2591.
https://doi.org/10.1182/blood-2019-127253
Published: 2019
Journal Articles

Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Dominik Wolf, MD, Jorn Skavland, PhD, Christoph Seger, PhD, Sieghart Sopper, PhD, Wiktor-Wieslaw Jedrzejczak, MD, PhD, Dubravka Sertic, MD, Jaroslava Voglova, MD, Satu Mustjoki, MD PhD, Leif Stenke, MD, PhD, Augustin Ferrant, MD, PhD, Richard Greil, MD, Alois Lang, MD, Josef Thaler, MD, PhD, Werner Linkesch, MD, Antica Duletić-Načinović, MD , PhD, Andrzej Hellmann, MD, PhD, Georgi G. Mihaylov, MD, PhD, Tobias Gedde-Dahl, III, MD, PhD, Henrik Hjorth-Hansen, MD, PhD, Waleed Majeed, MD, Jesper Stentoft, MD, Gregor Verhoef, M.D. Ph.D., Jan Van Droogenbroeck, MD, Ute Mark, Jens Haenig, Nidas Jurjonas, Frank Giles, MD MB, Andreas Hochhaus, MD, Kimmo Porkka, MD, PhD, Gert J. Ossenkoppele, MD PhD, Bjorn T. Gjertsen, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1485.
https://doi.org/10.1182/blood.V122.21.1485.1485
Published: 2013